Epithalon (also spelled Epitalon) is a tiny, artificially produced fragment of protein - a short chain of just four amino acids linked together (a so-called tetrapeptide: alanine, glutamic acid, aspartic acid and glycine; sequence Ala-Glu-Asp-Gly). The molecule is extremely small, with a molecular weight of 390 daltons. It was developed in the 1990s at the St. Petersburg Institute of Bioregulation and Gerontology by Russian researcher Vladimir Khavinson, designed to mimic a natural bovine pineal gland extract called Epithalamin. It is widely marketed in biohacking circles as an "anti-aging" compound, though this claim remains scientifically unproven in living humans. A critical distinction must be made: almost all historical human clinical data applies to the natural extract (Epithalamin), not the synthetic peptide (Epithalon). Transferring safety or efficacy data from the natural extract to the synthetic variant is scientifically invalid.

What is Epithalon?

Epithalon is a tiny synthetic tetrapeptide developed in Russia and widely marketed as an anti-aging compound. However, its ability to actually slow human aging is completely unproven, as no randomized clinical trials exist. It remains an unapproved, experimental research chemical with significant safety unknowns. Developed as a short peptide bioregulator, it is intended to influence cellular processes in a targeted way. While it is heavily promoted in longevity communities for its potential to extend cellular lifespan, experts emphasize that the data is strictly preliminary. Consumers must understand that Epithalon is not a proven medical therapy, but rather an experimental substance largely confined to laboratory research and unregulated self-experimentation.

How does Epithalon work?

Epithalon works by entering the cell nucleus and upregulating the hTERT gene, which increases the production of telomerase. This enzyme lengthens telomeres - the protective caps on chromosomes - allowing cells to divide beyond their natural limits, though it also activates mechanisms linked to cancer cell survival. Because of its very small size, Epithalon does not bind to classical docking sites on the cell surface. Instead, it is taken up directly into cells to interact with DNA and transcription factors. In laboratory studies using human fetal fibroblasts, this mechanism successfully extended the replicative lifespan of the cells beyond their natural Hayflick limit. Additionally, the peptide is believed to normalize circadian melatonin release via the pineal gland and regulate gene expression epigenetically, meaning it can switch genes on or off without altering the underlying DNA code.

How effective is Epithalon?

In laboratory cultures, Epithalon is highly effective at extending cellular lifespan and lengthening telomeres. However, its clinical effectiveness in living humans is entirely unproven. Almost all data originates from a single Russian research group, and no independent, randomized controlled trials have confirmed these anti-aging benefits. The overall quality of the evidence is graded as very low. A major point of confusion in evaluating its effectiveness stems from clinical data: a Russian study treating 162 patients with the retinal disease Retinitis pigmentosa used the natural precursor Epithalamin, not synthetic Epithalon. Without independent replication and rigorous human trials, the real-world effectiveness of Epithalon remains speculative, and it should not be regarded as settled science.

Substance	Class / Mechanism	Effect Magnitude	Status
Epithalon (AEDG)	Synthetic tetrapeptide (hTERT / Telomerase activation)	High in vitro, unproven in humans	Unapproved, FDA Category 2
Epithalamin	Natural bovine pineal extract	Moderate in limited older human trials	Unapproved (Legacy Russian research)
Thymalin	Thymus peptide extract (Immunomodulator)	Some clinical data (also Khavinson)	Local approval in Russia
GHK-Cu	Copper peptide (Tissue repair / Gene modulation)	Moderate (Topical / In vitro)	Cosmetic ingredient, unapproved for injection

Dosage: what the studies show - and the course

There are no medically approved dosages or validated clinical protocols for Epithalon. Biohacking communities typically use highly variable short courses of subcutaneous injections, ranging from 5 to 10 mg daily over 10 to 20 days, but these practices are strictly experimental and lack clinical oversight. None of these protocols are study-validated in modern clinical settings. Subcutaneous injection is favored in these unregulated communities due to its higher bioavailability (meaning more of the substance actually makes it into the bloodstream), whereas oral intake is considered far less effective as stomach acids can degrade the peptide.

Protocol (Biohacking)	Dose	Goal / Note
10-Day Cycle	5 to 10 mg daily	Injected subcutaneously in the evening before sleep, repeated 1 to 2 times per year.
20-Day Cycle	10 mg every other day	10 total injections spread over 20 days, repeated 1 to 2 times per year.
Maintenance	Break of 4 to 6 months	Cycle is only repeated after a longer pause.

Mixing & calculating dose

Epithalon is typically sold as a lyophilized powder that must be reconstituted with bacteriostatic water before subcutaneous injection. Calculating the correct dose requires precise mathematical dilution based on the vial's total mass, a process where biohackers frequently make dangerous concentration errors with unregulated products. For example, adding 2 mL of bacteriostatic water to a 10 mg vial yields a concentration of 5 mg per mL. Because these products are sold illegally as unregulated "Research Chemicals", the buyer has no pharmaceutical guarantee that the vial actually contains 10 mg of pure Epithalon. Misjudging the volume or starting with an inaccurately dosed vial can lead to severe dosing errors, underscoring the danger of self-administration without medical supervision.

Side effects and common mistakes

The side effect profile of synthetic Epithalon in humans is entirely undocumented. While animal studies show no toxicity, a major theoretical risk is cancer promotion, as activating telomerase can make malignant cells immortal. Additionally, unregulated black-market products frequently contain dangerous biological and chemical contaminants. Older reports from 2015 claimed a favorable safety profile, but these evaluations were based on the natural extract Epithalamin. A 2025 systematic review explicitly states that critical human safety data for Epithalon is missing. Furthermore, a 2025 independent laboratory study found that Epithalon triggers ALT activation (Alternative Lengthening of Telomeres) in cancer cell lines, a mechanism often associated with the survival of cancer cells. In animal models, no genotoxicity, kidney toxicity, or negative effects on body weight and muscle strength were observed.

Confusing synthetic and natural forms: Assuming synthetic Epithalon is a proven therapy based on older human trials that actually used the natural extract Epithalamin.
Ignoring cancer risks: Overlooking the fact that non-specific telomerase activation can potentially protect or immortalize pre-existing cancer cells.
Trusting unregulated products: Purchasing "Research Chemicals" online, which are frequently contaminated, under-dosed, or completely mislabeled.
Mishandling reconstitution: Making severe mathematical errors when diluting lyophilized powder, leading to massive accidental overdoses.

Approval and legal status

Epithalon has absolutely no medical approval anywhere in the world as an anti-aging or therapeutic drug. In the United States, it is categorized as an unapproved substance with significant safety concerns, and it remains strictly prohibited in legitimate pharmaceutical markets across the EU and globally. Until recently, Epithalon was explicitly listed by the US FDA on its Category 2 list of bulk drug substances with significant safety concerns. While it was recently scheduled for a Pharmacy Compounding Advisory Committee (PCAC) review, this is merely an administrative procedure and does not constitute approval or recognized safety. In Germany and the European Union, it is completely unapproved as a pharmaceutical, making its commercial sale for human consumption illegal. Its legal status is confined strictly to laboratory research, not medical application.

Evidence at a glance

Research status

Epitalon is a synthetic tetrapeptide based on the bovine pineal gland extract Epithalamin [1, 3]. Preclinical in vitro evidence in human cell lines shows telomere lengthening and neurogenesis [4, 5, 6, 7, 9, 11]. Animal studies indicate lifespan extension, cancer suppression, antioxidant, and anti-apoptotic effects [1, 7, 8, 12, 13, 17, 18]. However, robust human clinical data for synthetic Epitalon are lacking, as much of the cited human research used Epithalamin [24]. Epitalon is not approved for medical use outside of Russia [23], has been found in illegal pharmaceutical preparations [15], and the FDA has issued warning letters regarding its sale as an unapproved new drug [10].

Human evidence

There is a lack of robust, controlled human clinical trials for synthetic Epitalon [24]. One study reports that Epitalon therapy in patients with degenerative retinal lesions (Retinitis Pigmentosa) resulted in a positive clinical effect in 90% of cases [17]. However, the cited source for this study provides no details on the study design (e.g., control group, blinding, sample size), making the evidence grade unclear. Much of the human data often cited for Epitalon actually used Epithalamin, the related extract [24].

Dosages in studies & practice

In vitro: Human cell lines were treated with 0.2 to 1 μg/ml for 4 days [5]. Animal models: Female Swiss-derived SHR mice received 1.0 μg/mouse subcutaneously [13], while transgenic HER-2/neu mice received 1 mg subcutaneously 5 times a week [18]. Human protocols (often for Epithalamin): Reviewed clinical trials used different dosing with "no apparent standard." Common doses included intranasal delivery (10-30 mg/day for 20-30 days) and intramuscular injection (5-10 mg/day for 10-20 days) [23]. Anecdotal/Secondary source: A "typical research dose" of 10 mg/day subcutaneous injection for 10-20 day cycles is cited, though no primary pharmacokinetic validation is provided [10].

Risks & side effects

The FDA states that nonclinical studies were too limited in scope and duration to inform safety considerations for potential clinical uses of Epitalon [2]. The FDA also notes that because Epitalon activates telomerase and lengthens telomeres, it is "generally associated with increased risk for cancer" [2]. Furthermore, it has been identified in illegal pharmaceutical preparations [15], and the FDA has issued warning letters regarding its sale as an unapproved new drug [10].

Research gaps

There are no robust, controlled human clinical trials available for synthetic Epitalon in the cited sources [24]. The existing human study on retinitis pigmentosa lacks study design details such as control groups, blinding, and sample size [17]. Nonclinical studies are too limited in scope and duration to inform safety [2]. Additionally, there is no primary pharmacokinetic validation provided for typical research doses [10].

Editorial, sourced from primary literature - not medical advice.

Related peptides

Sources

← Back to peptides

Common use common practice, unverified